ReviewFrontiers in endocrinology2026
From the perspective of prolactin: a view on obesity.
Review in Frontiers in endocrinology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Lower prolactin levels are associated with histological severity of metabolic dysfunction-associated steatotic liver disease.BMC endocrine disorders · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The physiological roles of prolactin extend beyond its classical functions in reproductive regulation. Emerging evidence indicates that prolactin is involved in energy homeostasis and may interact pathophysiologically with obesity; this has attracted increasing attention in endocrinology and metabolic research. Hyperprolactinemia (HPRL) is frequently observed in obese individuals. Observational studies have reported that weight-loss interventions are associated with reduced circulating prolactin levels, whereas dopamine agonists, which suppress prolactin secretion, improve metabolic and endocrine abnormalities in patients with established hyperprolactinemia. Accumulating evidence suggests an association between hyperprolactinemia and obesity. However, the directionality and causality of this relationship remain unclear. Experimental and translational studies suggest that elevated prolactin levels contribute to obesity-related phenotypes through multiple pathways, including altered central appetite regulation, modulation of adipocyte differentiation and lipid storage, impairment of insulin sensitivity, and disruption of the hypothalamic-pituitary-gonadal (HPG) axis. In contrast, obesity may be associated with increased circulating prolactin levels, which are potentially mediated by adipose tissue expansion, enhanced aromatase-dependent estrogen production, and chronic low-grade systemic inflammation. This review aimed to provide a systematic synthesis of current evidence regarding the mechanistic links between hyperprolactinemia and obesity, with an emphasis on the biological properties of prolactin, clinical characteristics of obesity complicated by HPRL, and molecular and physiological pathways underlying their reciprocal interactions. In addition, we critically evaluate current clinical management strategies, including dopamine agonist therapy and lifestyle-based weight-loss interventions, highlighting existing uncertainties and future directions aimed at improving the diagnosis and integrated management of these frequently coexisting conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.